Welcome to your Daily Dose of Health Tech Innovation!
Stay ahead with the latest breakthroughs revolutionizing healthcare—from AI diagnostics to remote care solutions.
We bring you expert-curated insights, emerging trends, and must-know updates from the digital health frontier.
Whether you’re a clinician, innovator, or health tech enthusiast, this roundup delivers what matters most.
Let’s dive into the future of health, one innovation at a time.
Eleanor Health Joins Cigna and Evernorth Networks
Eleanor Health, a fully integrated behavioral health medical home focused on helping people dealing with substance use disorder (SUD), has now become part of the provider networks for Cigna Healthcare and Evernorth Behavioral Health. This is a big step in making evidence-based mental health and addiction treatment more widely available across the United States. The partnership will initially serve over 4.7 million insured individuals in 15 states, including Florida, Louisiana, Ohio, New Jersey, North Carolina, Massachusetts, Washington, Texas, Colorado, Missouri, New Mexico, Pennsylvania, Montana, Idaho, and Illinois. In these areas, about 366,000 people are currently living with substance use challenges, which shows how important it is to have comprehensive and accessible care.
Halozyme to Acquire Elektrofi for Drug Delivery Expansion
Halozyme Therapeutics, Inc. announced that it has entered into a final agreement to purchase Elektrofi, Inc., a biopharmaceutical company that develops a revolutionary ultra-high concentration microparticle technology for biologics called Hypercon. The deal includes a $750 million upfront payment, along with up to three additional $50 million payments linked to regulatory clearances for certain products. Both companies’ boards of directors have approved the transaction unanimously.
Biocon Sets U.S. Launch Date for Denosumab Biosimilars
Biocon Biologics Ltd., a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has announced that it has reached a settlement and licensing agreement with Amgen Inc. This agreement allows for the U.S. commercialization of Bosaya (denosumab-kyqq) and Aukelso (denosumab-kyqq). The deal resolves ongoing patent issues in the U.S. District Court for the District of New Jersey, enabling Biocon Biologics to start the U.S. launch of both products on October 1, 2025. Several terms of the agreement remain confidential.
Clarivate Unveils AI Tools for Patent Analysis in Innography
Clarivate Plc, a global leader in intelligence solutions, has launched two new AI-powered features for its Innography platform: the Innography AI Classifier, which improves portfolio benchmarking, and the Innography SEP Analyzer, which supports standard essential patent (SEP) negotiations. These additions align with Innography’s mission to connect patent insights with business strategy, helping organizations make quicker and more informed choices in managing their patent portfolios, licensing, and commercialization efforts.
WallachBeth Capital Announces Closing of bioAffinity Technologies Public Offering for $4.8 million
WallachBeth Capital LLC, a well-known firm that focuses on capital markets and institutional trading, shared that bioAffinity Technologies, Inc., a biotech company working on noninvasive early cancer detection tests, has finished its latest public offering. The company collected a total of $4.8 million before subtracting any fees or other costs.
To share your insights, please write to us at sudipto@intentamplify.com
